NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Thanks for your comments.

Data collected from ECA comparison only comprises a fraction of the clinical efficacy data that exists for murcidencel today.

Murcidencel has been studied in three trials—only one of those three relied on an ECA. All clinical data are relevant to a regulatory application including those data gathered from other studies and compassionate use. All three trials have produced substantial safety and efficacy data, and two of the three clinical trials ran for over a decade with survivors alive today.

Here is the Keytruda trial currently underway at UCLA. It is registered on the U.S. National Institutes of Health clinical trial registry. This study is not using chemo or radiation for any trial participants:

https://clinicaltrials.gov/ct2/show/NCT04201873



Murcidencel (DCVax-L) is discussed beginning at minute 40, to focus on Keytruda (pembrolizumab) plus DCVax in combo at UCLA, skip to minute 45:40

The ICLC trial is the second long-running study. Liau will be presenting analysis of the ICLC murcidencel data soon—keep an eye out for the date and venue! I believe she said that it will be at an academic conference.



The P3 clinical trial is the well-publicized study that has gotten more attention than the other clinical studies since it was published in JAMA:




https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847